GLP-1s Are Now Most Obesity Care for Teens: What to Ask
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Medication has almost entirely replaced surgery as the treatment young people receive for obesity. A study of more than 204,000 patients aged 13 to 25 found that GLP-1 medications accounted for 96.1% of obesity treatment by early 2026, up from 88.2% in 2022, while bariatric surgery fell from 11.6% to 3.7% (JAMA Pediatrics). Two medicines are FDA-approved from age 12, others are not approved for this age group at all, and most telehealth services will not treat minors. Knowing which is which is the first thing to sort out.
Who This Helps
This is for parents and caregivers of a teenager or young adult who has raised the idea of a GLP-1, and for young adults weighing it for themselves. It covers what the new data show, what is approved at what age, and the questions worth asking before anything starts.
What Did the New Study Find?
Researchers at UT Southwestern reviewed records for 204,000 patients aged 13 to 25 receiving obesity treatment and tracked what that treatment consisted of over time (UT Southwestern). The shift they documented was rapid.
- Exclusive GLP-1 use: 88.2% of treatment in 2022, rising to 96.1% by early 2026.
- Bariatric surgery: 11.6% of treatment in 2022, falling to 3.7% by early 2026.
A related finding is that prescribing to adolescents specifically grew from a very small base, and that access has not been even across groups, with differences by sex and race (JAMA Pediatrics). The study describes what care is being delivered rather than comparing how well the two approaches work, so it is not evidence that one is better than the other.
Which GLP-1s Are Approved for Teenagers?
Age approvals differ by medicine, and the difference matters more than brand familiarity. Keeping the comparison parallel makes it easier to hold onto.
- Wegovy (semaglutide): approved for weight management in patients aged 12 and older with obesity (Wegovy Prescribing Information).
- Saxenda (liraglutide): approved for weight management in patients aged 12 and older.
- Zepbound (tirzepatide): approved for adults, so use in someone under 18 falls outside the approved population.
- Ozempic and Mounjaro: approved for type 2 diabetes in adults, not for weight management in adolescents.
Prescribing a medicine outside its approved population is called off-label use. A clinician may do it when they judge it appropriate, and the FDA is explicit that it has not determined the drug is safe and effective for that use (FDA). For a young person, that trade-off deserves a direct conversation rather than a footnote.
Will a Telehealth Service Treat a Minor?
Usually not. Most direct-to-consumer telehealth weight-loss services set 18 as their minimum age, so a parent looking for a fast online route will often find the door closed, and that is not likely to change soon. Adolescent obesity care is built around ongoing assessment, growth and puberty considerations, nutrition support, and mental health screening, which is difficult to deliver through a subscription intake form.
What this means for you: start with your pediatrician or a pediatric weight-management program rather than a telehealth platform. If you do end up comparing telehealth options for a young adult over 18, our guide to evaluating telehealth and compounded GLP-1 providers covers what to verify first.
What Does Good Care Look Like at This Age?
Pediatric guidance treats medication as one component of comprehensive treatment rather than the whole plan. The American Academy of Pediatrics recommends intensive health behavior and lifestyle treatment for children and adolescents with obesity, and discusses pharmacotherapy as an addition to that care for adolescents 12 and older rather than a replacement for it (American Academy of Pediatrics).
Practically, that means asking what else comes with the prescription: nutrition support the family can actually follow, activity that fits the young person's life, sleep and school considerations, follow-up visits, and attention to how they feel about their body along the way.
What Should You Ask About Side Effects and Growth?
The common side effects in adolescents resemble those in adults, mostly stomach-related, including nausea, vomiting, diarrhea, and constipation, and the labeling carries the same boxed warning about thyroid tumors seen in rodent studies along with the same contraindications (Wegovy Prescribing Information).
Two additional questions belong in a pediatric conversation. Ask how growth, puberty, and nutritional adequacy will be monitored while weight is changing. And ask about muscle and bone, since the American College of Physicians directs clinicians to counsel patients about side effects of weight loss itself, including muscle and bone density loss (American College of Physicians).
Is This a Short Course or a Long Commitment?
Treat it as an open question to ask directly, because the adult evidence points toward ongoing treatment. When people stop a GLP-1, weight and cardiometabolic markers tend to move back toward where they started, and 2026 trial data found that continuing treatment, or continuing at a reduced dose, preserved far more of the benefit than stopping. Our article on what happens after you stop a GLP-1 covers that evidence in detail.
The framing clinicians increasingly use is that this is a chronic condition rather than a short project. Announcing the ACP's 2026 guideline, its president, Jan K. Carney, MD, MPH, said: "Overweight and obesity are chronic, progressive conditions that raise the risk of significant health complications and reduce life expectancy" (American College of Physicians).
For a 14-year-old, the honest framing is that nobody has decades of data on starting in adolescence, so the plan should include how long, how it will be reassessed, and what happens if the family wants to stop.
Questions to Bring to the Pediatrician
- Is this medicine approved for my child's age, or would this be off-label, and why do you recommend it either way?
- What does the full plan include besides the prescription, and who provides those parts?
- How will you monitor growth, puberty, nutrition, and muscle and bone health?
- What are we hoping to change, and how will we know whether it is working?
- How long do you expect treatment to continue, and how will we revisit that?
- What is the plan if we decide to stop, and what should we expect afterward?
- Is there a mental health component, and how will you check in on how my child feels about their body?
A Note on How This Conversation Lands
How a family talks about weight matters as much as what is prescribed. Conversations that center health, energy, and how a young person feels tend to land better than ones centered on appearance or numbers, and a clinician can help set that tone.
If a young person's relationship with food or their body seems distressed, say so to the pediatrician plainly. That changes what kind of support is appropriate, and it is a normal thing to raise rather than something to keep quiet about.
Final Takeaway
Medication is now nearly the whole picture of obesity treatment for teens and young adults, and surgery has become rare in this age group.
Approvals are narrower than the headlines suggest. Two medicines are approved from age 12, the popular tirzepatide products are adult-only, and most telehealth services will not see a minor at all.
Start with a pediatrician rather than an online intake form, and ask what surrounds the prescription. Nutrition, follow-up, growth monitoring, and mental health are the parts that make medication work.
Ask about the long horizon too. The adult evidence suggests benefits fade when treatment stops, so the plan should say how long and how it gets revisited.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Can a teenager take a GLP-1 for weight loss?
Two medicines are FDA-approved for weight management from age 12, semaglutide sold as Wegovy and liraglutide sold as Saxenda. Whether one is appropriate for a specific young person is a decision for their pediatrician, alongside comprehensive care.
Is Zepbound approved for teens?
No. Tirzepatide products including Zepbound are approved for adults, so use in someone under 18 would be off-label. The FDA notes it has not determined a drug is safe and effective for uses outside its approval.
Why did the study find GLP-1s are 96% of treatment for young people?
A 2026 study of more than 204,000 patients aged 13 to 25 found exclusive GLP-1 use rose from 88.2% in 2022 to 96.1% by early 2026, while bariatric surgery fell from 11.6% to 3.7%. The study describes what care was delivered rather than which approach works better.
Will an online telehealth service prescribe a GLP-1 to my teenager?
Most direct-to-consumer telehealth weight-loss services require patients to be 18 or older. Adolescent care generally belongs with a pediatrician or a pediatric weight-management program that can monitor growth, nutrition, and mental health.
What should I ask before my child starts a GLP-1?
Ask whether the medicine is approved for their age or off-label, what the plan includes besides the prescription, how growth and nutrition will be monitored, how long treatment is expected to last, and what happens if you decide to stop.
Sources
Keep Reading
Major GLP-1 and obesity drug trials are finishing in 2027. Here’s what they’re studying and what it could mean for access and affordability.
A Stanford study of 5,000+ GLP-1 users found that small behavior changes make a real difference. Here are the 8 microsteps and how to start.
A Penn Medicine study of 110,000+ women links GLP-1 use to about 30% lower breast cancer risk. See what it found, its limits, and what it means.
Categories
Curated by
